The intensive studies of human genome and genome sequencing of a large number of patients demonstrated that MEF2C should be considered as a candidate risk gene in a variety of neuropsychiatric disorders, including Alzheimer’s disease (AD) [120], autism spectrum disorders [121], schizophrenia [122], bipolar disorder [123], Angelman syndrome [124], major depression [125], attention deficit and hyperactivity disorder [126], epilepsy [127] and Parkinson’s disease [128]. The gene discussed is MEF2C; the disease is epilepsy.